Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study
- Conditions
- Heart Disease
- Registration Number
- NCT05484882
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Brief Summary
Background:
The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why.
Objective:
This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study.
Eligibility:
African Americans who were previously enrolled in GENE-FORECAST.
Design:
The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities.
The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic.
The clinic visit will last up to 4 hours.
Participants will have a physical exam. They will have blood and urine tests.
They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose.
They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm.
Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs.
Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play....
- Detailed Description
STUDY DESCRIPTION
The objective is to conduct a prospective natural history study of Coronavirus disease 2019 (COVID-19) among a community-based cohort of African Americans enrolled in GENE-FORECAST for whom we have comprehensive psychosocial, clinical, and genetic data collected at baseline. Participants will be invited to take part in a 20-minute computer-assisted telephone interview (CATI) on exposures, attitudes and circumstances during the COVID-19 pandemic and to undergo a clinic visit for a physical exam, vascular function tests and biospecimen collection. We will identify social, clinical and genetic risk factors for COVID-19 and examine the interplay between social determinants of health and personal risk profiles to better understand the disparate burden of COVID-19 in the African American community. It is hypothesized that exposure to the SARS-CoV-2 virus and the development of COVID-19 will be associated with social and neighborhood factors, and that SARS-CoV-2 infection will adversely affect vascular function.
OBJECTIVES
Primary Objectives:
1. Define the effect of social factors (e.g., socio-economic status; neighborhood characteristics) on exposure to SARS-CoV-2 and the development of COVID-19.
2. Define the effect of SARS-CoV-2 infection and the development of COVID-19 on vascular function (e.g., pulse wave velocity).
3. Examine how social factors influence the effect of SARS-CoV-2 and COVID-19 on vascular function.
Secondary Objectives:
1. Examine the effects of SARS-CoV-2 infection and COVID-19 on epigenome (whole-blood), transcriptome, (whole-blood, plasma
microvesicles, urine), peripheral blood mononuclear cell (PBMC) single-cell RNA-seq, biomarker profile (e.g., CRP; d-dimer), cardiac function (EKG) and leukocyte telomere length.
2. Examine how social factors influence the effect of SARS-CoV-2 infection and COVID-19 on transcriptome and epigenome.
ENDPOINTS
Primary Endpoints:
SARS-CoV-2 infection
Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia)
Secondary Endpoints:
Transcriptome (whole-blood, plasma microvesicles, urine)
Epigenome (whole-blood)
PBMC single-cell RNA-seq
Leukocyte telomere length
Electrocardiogram (EKG)
Biomarker profile (CRP, D-Dimer, ACE-2, HS-Troponin)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 431
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Define the effect of social factors (e.g., socio-economic status; neighborhood characteristics) on exposure to SARS-CoV-2 and the development of COVID-19 48 month Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia)
Define the effect of SARS-CoV-2 infection and the development of COVID-19 on vascular function (e.g., pulse wave velocity). 48 month Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia)
Examine how social factors influence the effect of SARS-CoV-2 and COVID-19 on vascular function. 48 month African Americans are disproportionately affected by SARS-CoV-2 infection and COVID-19. There are well-documented socioeconomic inequalities that contribute to this increased vulnerability. The disparate burden of disease demands a multidimensional approach informed by social determinants of health, geography (neighborhood), and personalized risk profiles. Among the social, environmental, clinical and genetic factors likely to be important for COVID-19 risks and outcomes, there is little understanding of the relative importance of these factors among African Americans and how they interact to affect morbidity and mortality.
- Secondary Outcome Measures
Name Time Method Examine how social factors influence the effect of SARS-CoV-2 infection and COVID-19 on transcriptome and epigenome. 48 month Biomarker profile (CRP, D-Dimer, ACE-2, HS-Troponin) \* Analyses of all of the above endpoints will use change in values from baseline GENE-FORECAST to current measures.
Examine the effects of SARS-CoV-2 infection and COVID-19 on epigenome (whole-blood), transcriptome, (whole-blood, plasma microvesicles, urine), peripheral blood mononuclear cell (PBMC) single-cell RNA-seq, biomarker profile (e.g., CRP; d-dimer),... 48 month Transcriptome (whole-blood, plasma microvesicles, urine) Epigenome (whole-blood) PBMC single-cell RNA-seq Leukocyte telomere length
Trial Locations
- Locations (2)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States
Westat, Inc.
🇺🇸Rockville, Maryland, United States